High-residual platelet activity despite dual antiplatelet treatment associated with subacute stent thrombosis

High-residual platelet activity despite dual antiplatelet treatment associated with subacute stent thrombosis

Bibliographic Details
Main Authors:	Malý Martin, Hadačová Ivana, Hájek Petr, Zemánek David, Veselka Josef
Format:	Article
Language:	English
Published:	De Gruyter 2009-03-01
Series:	Open Medicine
Subjects:	resistance dual antiplatelet therapy stent thrombosis light transmittance aggregometry clopidogrel
Online Access:	https://doi.org/10.2478/s11536-009-0007-8

Similar Items

Antiplatelet Therapy in the Patient with Coronary Stent Undergoing Surgery and Dental Procedure
by: Noppadol Chamnarnphol
Published: (2011-04-01)

Comparing of Light Transmittance Aggregometry and Modified Thrombelastograph in Predicting Clinical Outcomes in Chinese Patients Undergoing Coronary Stenting with Clopidogrel
by: Xiao-Fang Tang, et al.
Published: (2015-01-01)

INDIVIDUAL ANTIPLATELET THERAPY IN PATIENTS WITH ATHEROSCLEROSIS OF LOWER EXTREMITIES: MYTH OR REALITY?
by: O. V. Sirotkina, et al.
Published: (2018-01-01)

Pharmacogenomic Testing and Antithrombotic Therapy: Ready for Prime Time?
by: David R. Holmes, Jr.
Published: (2013-01-01)

Effectiveness of Two-Year versus One-Year Use of Dual Antiplatelet Therapy in Reducing the Risk of Very Late Stent Thrombosis after Drug-Eluting Stent Implantation
by: Hamid Reza Poorhosseini, et al.
Published: (2012-04-01)

Effectiveness of Two-Year Versus One-Year Use of Dual Antiplatelet Therapy in Reducing the Risk of Very Late Stent Thrombosis After Drug-Eluting Stent Implantation
by: Ali Reza Amirzadegan, et al.
Published: (2012-06-01)

Decreased threshold of aggregation to low-dose epinephrine is evidence of platelet hyperaggregability in patients with thrombosis
by: Chelsea Hayes, et al.
Published: (2014-08-01)

FEATURES OF PLATELET HEMOSTASIS IN PATIENTS WITH VARIOUS SENSITIVITY TO ANTIPLATELET THERAPY IN STABLE ANGINA PECTORIS AFTER PLANNED PERCUTANEOUS CORONARY INTERVENTION
by: Pronko T. P., et al.
Published: (2017-12-01)

The effect of doubling the dose of clopidogrel on platelet aggregation in patients with clopidogrel resistance
by: John I. Louca, et al.
Published: (2014-09-01)

SUB-ACUTE STENT THROMBOSIS AND IN-STENT RESTENOSIS ASSOCIATED WITH ANTIPLATELETS CLOPIDOGREL RESISTANCE AND PROTEIN S DEFICIENCY
by: M Zakky Kurniawan, et al.
Published: (2016-11-01)

Best duration of dual antiplatelet therapy after drug-eluting stent implantation: an updated network meta-analysis of randomized controlled trials
by: Mahmoud Barbarawi, et al.
Published: (2019-01-01)

Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications
by: Katalin Koltai, et al.
Published: (2017-08-01)

EVALUATION OF PLATELET AGGREGATION IN CLINICAL PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Stent thrombosis associated with drug eluting stents on addition of cilostazol to the standard dual antiplatelet therapy following percutaneous coronary intervention: a systematic review and meta-analysis of published randomized controlled trials
by: Feng Huang
Published: (2018-06-01)

Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?
by: Berger Peter B
Published: (2000-10-01)

Change of Platelet Reactivity to Antiplatelet Therapy after Stenting Procedure for Cerebral Artery Stenosis: VerifyNow Antiplatelet Assay before and after Stenting
by: Deok Hee Lee, et al.
Published: (2012-02-01)

THE SIGNIFICANCE OF PLATELET FUNCTIONAL ACTIVITY TESTING IN THE PREVENTION OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS RECEIVING ANTIPLATELET THERAPY
by: D. A. Andreev
Published: (2015-09-01)

Thrombelastographic haemostatic status and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): assessing and monitoring the antithrombotic effect of clopidogrel and aspirin versus aspirin alone in hypercoagulable patients: study protocol for a randomized controlled trial
by: Rafiq Sulman, et al.
Published: (2012-04-01)

Antiplatelet Activity of Coumarins: In Vitro Assays on COX-1
by: Cristina Zaragozá, et al.
Published: (2021-05-01)

OPTIMA Tacrolimus-eluting Stent: A Twelve-month Clinical Follow up with Two Different Periods of Dual Antiplatelet Therapy; 2-monthvs. 6-month Approach
by: Nasser Aslanabadi, et al.
Published: (2012-09-01)

Comparison of antiplatelet activity of garlic tablets with cardio-protective dose of aspirin in healthy volunteers: a randomized clinical trial
by: Mojtaba Shafiekhani, et al.
Published: (2016-08-01)

Why Me? To Be an Ultra-Responder to Antiplatelet Therapy: A Case Report
by: Francesca Rosafio, et al.
Published: (2021-08-01)

What is the Optimal Duration of Dual Antiplatelet Therapy After Stenting?
by: Udaya S. Tantry, PhD, et al.
Published: (2016-05-01)

Omeprazol y clopidogrel asociado a trombosis de stent
by: Ricardo Amador García Hernández, et al.

Non-responsiveness to oral antiplatelet treatment
by: Rok Perme, et al.
Published: (2006-10-01)

Clinical Impact of Dual Antiplatelet Therapy Use in Patients Following Everolimus-eluting Stent Implantation: Insights from the SEEDS Study
by: Yao-Jun Zhang, et al.
Published: (2015-01-01)

Shorter- versus Longer-duration Dual Antiplatelet Therapy in Patients with Diabetes Mellitus Undergoing Drug-eluting Stents Implantation: A Meta-analysis of Randomized Controlled Trials
by: He Huang, et al.
Published: (2016-01-01)

Antiplatelet Therapy in a Patient with Coronary Artery Disease and Myelodysplastic Syndrome with Thrombocytopenia
by: Francisco José Fernández-Fernández, et al.
Published: (2017-10-01)

THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS
by: O. V. Gaisenok
Published: (2016-01-01)

Ticagrelor as an Alternative Antiplatelet Therapy in Cardiac Patients Non-Sensitive to Aspirin
by: Hamzah Khan, et al.
Published: (2020-10-01)

RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: D. H. Aynetdinova, et al.
Published: (2015-12-01)

Recovery Time of Platelet Function After Aspirin Withdrawal
by: Jeonghun Lee, MD, et al.
Published: (2014-12-01)

PHARMACOGENETIC BASES OF INDIVIDUAL SENSITIVITY AND PERSONALIZED ADMINISTRATION OF ANTIPLATELET THERAPY IN DIFFERENT ETHNIC GROUPS
by: B. I. Kantemirova, et al.
Published: (2021-05-01)

Antiplatelet Therapy Discontinuation and the Risk of Serious Cardiovascular Events after Coronary Stenting: Observations from the CREDO-Kyoto Registry Cohort-2
by: Watanabe, Hirotoshi
Published: (2016)

Incidence of major adverse cardiovascular events with genotype test guided antiplatelet treatment strategy after percutaneous coronary intervention
by: S. Ramesh, et al.
Published: (2020-11-01)

UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE
by: S. Yu. Martsevich, et al.
Published: (2015-12-01)

Duration of antiplatelet therapy cessation before coronary artery bypass surgery: Relation with platelet count
by: Sushil Prakash Ambesh
Published: (2015-07-01)

High residual platelet reactivity during dual antiplatelet therapy, found by optical aggregometry and the rate of atherothrombotic complications after coronary artery stenting in patients with ischemic heart disease in clinical practice
by: N. F. Puchinyan, et al.
Published: (2016-09-01)

Antiplatelet resistance and thromboembolic complications in neurointerventional procedures
by: Thomas J Oxley, et al.
Published: (2011-12-01)

ASSOCIATION BETWEEN SMOKING AND THE ANTIPLATELET EFFECT OF CLOPIDOGREL
by: K. Yu. Lukianets, et al.
Published: (2020-10-01)